
FDA Grants Priority Review for Lurbinectedin/Atezolizumab in ES-SCLC
The FDA granted priority review to the combination of lurbinectedin (Zepzelca) and atezolizumab (Tecentriq) as a first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC), with a Prescription Drug User Fee Act (PDUFA) target …